List/Grid

Oncology Subscribe to Oncology

Customizing chemotherapy in lung cancer: New phase II data reported

Customizing chemotherapy in lung cancer: New phase II data reported

Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown at the ESMO 2014 Congress in Madrid. In a randomized phase II study, researchers showed that patients whose lung cancers expressed low levels of an enzyme called thymidylate synthase experienced a greater benefit from treatment with the combination of pemetrexed and cisplatin than those whose tumours expressed high levels. “Thymidylate synthase is one of the proteins that is targeted by pemetrexed which is the most widely used chemotherapeutic regimen in the treatment of non-squamous NSCLC,” explains study author Professor Myung-Ju Ahn, from the Section of Hematology-Oncology at Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Continue reading

Chemotherapy: Rolapitant reduces nausea and vomiting in phase III trial

Chemotherapy: Rolapitant reduces nausea and vomiting in phase III trial

Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain. Dr Martin Chasen, lead author and medical director, Palliative Care, Ottawa Hospital Cancer Centre, Canada, said: “This agent makes a significant difference in the way people tolerate their chemotherapy. Patients experienced no loss in quality of life and, in fact, many saw meaningful improvements Continue reading

Many Patients Excluded From Lung Cancer Clinical Trials Due to Prior Cancer, Study Finds

Many Patients Excluded From Lung Cancer Clinical Trials Due to Prior Cancer, Study Finds

Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center. Among more than 50 lung cancer clinical trials examined, more than 80 percent excluded patients with prior cancer from participating, according to the study published in the Journal of the National Cancer Institute Continue reading

Researchers engineer ‘Cas9′ animal models to study disease, inform drug discovery

Researchers engineer ‘Cas9′ animal models to study disease, inform drug discovery

Researchers from the Broad Institute and Massachusetts Institute of Technology have created a new mouse model to simplify application of the CRISPR-Cas9 system for in vivo genome editing experiments. The researchers successfully used the new “Cas9 mouse” model to edit multiple genes in a variety of cell types, and to model lung adenocarcinoma, one of the most lethal human cancers. Continue reading

Bacterial ‘communication system’ could be used to stop, kill cancer cells, study finds

Bacterial ‘communication system’ could be used to stop, kill cancer cells, study finds

Cancer, while always dangerous, truly becomes life-threatening when cancer cells begin to spread to different areas throughout the body. Now, researchers at the University of Missouri have discovered that a molecule used as a communication system by bacteria can be manipulated to prevent cancer cells from spreading. Senthil Kumar, an assistant research professor and assistant director of the Comparative Oncology and Epigenetics Laboratory at the MU College of Veterinary Medicine, says this communication system can be used to “tell” cancer cells how to act, or even to die on command. Continue reading

Modest acute changes in cardiac biomarkers, electrocardiogram findings following thoracic radiation therapy

Modest acute changes in cardiac biomarkers, electrocardiogram findings following thoracic radiation therapy

There were only modest acute changes in cardiac biomarkers and electrocardiograms and there were no clinically significant cardiac events in patients with high-dose radiation exposure to the heart following thoracic radiation therapy (RT) and short-term follow-up. Radiation therapy is standard of care for some patients with thoracic malignancies such as lung cancer, esophageal cancer, thymoma, or malignant mesothelioma Continue reading

Most breast cancer patients who had healthy breast removed at peace with decision

Most breast cancer patients who had healthy breast removed at peace with decision

More women with cancer in one breast are opting to have both breasts removed to reduce their risk of future cancer. New research shows that in the long term, most have no regrets. Continue reading

Some patients with advanced, incurable cancer denied palliative care

Some patients with advanced, incurable cancer denied palliative care

Many patients with advanced, incurable cancer do not receive any palliative care, reveals new research to be presented later this month at the ESMO 2014 Congress in Madrid, Spain, 26-30 September. The findings are astonishing as they come at the same time as 15 new oncology centres in Europe, Canada, South America and Africa are being awarded the title of ‘ESMO Designated Centre of Integrated Oncology and Palliative Care.’ SR I Dr Alexandru Grigorescu, medical oncology consultant at the Institute of Oncology Bucharest, Romania, member of the ESMO Palliative Care Working Group, said: “The integration of palliative care in oncology is a challenge. This is especially the case for countries with few resources, where the healthcare budget is low, with insufficient palliative care specialists and some drugs are unavailable as hospitals do not have the funds to buy them.” “ESMO brings a new approach to palliative care, namely by integrating it with specific anticancer treatment conducted in medical oncology departments,” continued Grigorescu Continue reading

Role of hormone in response to ovarian cancer treatment

Role of hormone in response to ovarian cancer treatment

Researchers at Women & Infants Hospital of Rhode Island recently published the results of an investigation into how we might better tailor therapy for ovarian cancer. The work comes out of the molecular therapeutic laboratory directed by Richard G. Moore, MD, of Women & Infants’ Program in Women’s Oncology. Continue reading

Role of hormone in response to ovarian cancer treatment

Role of hormone in response to ovarian cancer treatment

Researchers at Women & Infants Hospital of Rhode Island recently published the results of an investigation into how we might better tailor therapy for ovarian cancer. Continue reading